Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours
about
In silico modelling of treatment-induced tumour cell kill: developments and advancesUse of Accelerator Mass Spectrometry in Human Health and Molecular ToxicologyPhase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumoursPhase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma.Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancerPharmacokinetically guided administration of chemotherapeutic agents.Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cellsA microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance.Progress in personalizing chemotherapy for bladder cancerNucleotide excision repair and anti-cancer chemotherapyAssociations between ABCC2 polymorphisms and cisplatin disposition and efficacyPlatinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapyPhase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancerAdaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma.ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer.Oxaliplatin-DNA adduct formation in white blood cells of cancer patientsPersonalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines.Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearanceDNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.Fluorometric imaging methods for palladium and platinum and the use of palladium for imaging biomolecules.A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.Comet assay measures of DNA damage are predictive of bladder cancer cell treatment sensitivity in vitro and outcome in vivo.Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing.Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report.Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei.Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis.Final results of a phase II single-institutional trial with hyperfractionated radiation therapy (HFX) and four-weekly continuous cisplatin in locally advanced head and neck carcinoma.Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer.Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow?
P2860
Q27011493-4852AAA3-7CD6-44D1-906F-AF25CBC8A35AQ28818313-F95BC8AE-0F60-4C7B-B435-6E77A857C528Q33369069-B57A9287-243F-4101-BDAC-C8DF3B127CBDQ33404428-7CE7C532-A2EA-4B5C-9D28-8850D3DA59E4Q33909699-7144AC11-6F68-4B36-89E7-8721ACDB2974Q34099816-A8AEE0D8-65FD-4129-BCAD-AD9AA27F310FQ34328748-DDEAA6B0-8E0D-4A32-AB18-3BDB7A4812BEQ35131936-15A00F20-2854-4178-8A43-4F58910B9574Q35779460-EA068659-9C9D-44D9-B2BA-7BDE9E910DC4Q36254803-80DC32FA-E739-49CF-B6B4-B43A99B9383BQ36352809-0ED7497D-E29B-4D0C-9343-3289BE7BC4C0Q36431475-FB95C8D3-7FAC-4BD7-B62E-59757C946392Q36597012-F4CA9B86-3385-4D65-BEDC-7296884886FAQ36609993-920E596A-B5D5-48FE-B9B3-E37BF31B5E20Q36615053-DDCDFDD7-35EC-4D5C-BB44-0BD3B04E3838Q36615632-6B54A807-05AD-47EF-B7EA-AA4B657961DFQ36617271-C7894699-0F1F-4E28-84AC-A00CF2D9B493Q36648829-4E6E3A0C-5F5E-4AF4-8EE9-6E94227DC4DEQ36740632-8549E726-FA48-4D8C-8DF3-FE2E4CD6C088Q36817080-C8DAC4EC-A0CE-448D-8038-04B8DBC3F212Q36948510-5D50DB6A-C603-4002-9F12-E7BFBD7F3A45Q37320350-36267486-5A4E-4C1E-88F4-5C44B880FB28Q37736567-EFC4BFEC-E25F-40FD-BBF7-E65DDF8D020AQ38364149-6A381448-3070-4DF5-8687-60BCE25C65E3Q38706298-CBCE6A96-753E-4BFE-9476-3EDCAD62BB54Q38728212-C269A75E-0FD8-4035-863F-96C09A4E441DQ39107932-41ADD6BD-AFF0-4A24-859C-D6C6CDF8A762Q40036508-853D16D3-5769-41C6-B56E-C971DE888F3CQ41276800-8ED72AEC-39FB-4AF8-B398-35299551F7FAQ41947874-7941A0BA-C5B4-43CE-84FF-9E03EEFC9D21Q42144353-23B2A74A-2D78-4917-A1FC-AEAC82EFA9A9Q43157204-A9DF7BE2-1769-464C-84AA-29D6C09F97A3Q43189722-A8BB51D5-7E34-4D1B-A05B-9EA906D27754Q45079279-DFA6DED1-7A60-4597-8982-5E16B5AFABD9Q46815487-7FF85F2C-423A-47C5-A555-06D398C461E5Q46980070-316F20F6-07B5-4984-B2F0-EB67EAD75EFBQ50457861-6598536B-87BA-4DA4-B3AE-F9ED58D25CEFQ50732583-83F3A175-C5A5-4BEF-9A16-191003142171
P2860
Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Relationship between the expos ...... in patients with solid tumours
@ast
Relationship between the expos ...... in patients with solid tumours
@en
type
label
Relationship between the expos ...... in patients with solid tumours
@ast
Relationship between the expos ...... in patients with solid tumours
@en
prefLabel
Relationship between the expos ...... in patients with solid tumours
@ast
Relationship between the expos ...... in patients with solid tumours
@en
P2093
P2860
P356
P1476
Relationship between the expos ...... in patients with solid tumours
@en
P2093
Planting AS
Schellens JH
Schmitz PI
de Boer-Dennert M
van Meerten E
van der Burg ME
P2860
P2888
P304
P356
10.1038/BJC.1996.296
P407
P577
1996-06-01T00:00:00Z